Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period
Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease
No safety signals were associated with alvelestat
Conference Call Today at 10:30 a.m. ET
